summit clinical trial tirzepatide JACC - #ACC25: A recent #JACC publication on the evaluates in patients with #HFpEF, with secondary analyses focusing on (1) cardiac structure and (2) #CKD. https://bit.ly/3EdDCQK Tirzepatide Reduces Heart Failure Risk

Those with excess weight, obesity, type 2 diabetes, prediabetes, or weight-related health conditions who have struggled with diet and exercise alone

For a thorough comparison beyond just dosing, the tirzepatide vs semaglutide dosage chart covers efficacy, side effects, and cost considerations

Theriogenology 64 , 29 (2018)

Gabriel D

In the STEP-HFpEF trial, treatment with 2.4 mg of the glucagon-like peptide-1 receptor agonist semaglutide weekly produced substantial improvements in symptoms, physical limitations and exercise function and reduced inflammation and resulted in greater weight loss compared to placebo 11,12

Hayes RP, DeLozier AM